Clinical trial
Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)
NCT07932132 is registered in ClinicalTrials.gov with Liaoning Chengda Biotechnology CO., LTD as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Recruiting, started August 2026. Interventional study, Phase 4, 160 participants (estimated). Lead sponsor Liaoning Chengda Biotechnology CO., LTD; China. Primary measures: Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14...; Incidence of adverse events after vaccination.
How it compares
12 similar trials: same condition (Rabies) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)
- Lead sponsor
- Liaoning Chengda Biotechnology CO., LTD
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- August 8, 2026
- Completion date
- June 30, 2028
- Enrollment
- 160 (estimated)
- Sites
- 2
Conditions
MeSH condition names; the registry's own terms follow.
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 2
- Countries
- China
- Lead sponsor
- Liaoning Chengda Biotechnology CO., LTD
Arms
As registered; 4 arms.
| Arm | Type | Interventions |
|---|---|---|
| Zagreb regimen (CD4+ T cell count ≥350 cells/mm³) | Experimental | Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried |
Show registry wordingEligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7, and 1 dose on day 21, for a total of 4 doses. | ||
| Essen regimen (CD4+ T cell count ≥350 cells/mm³) | Experimental | Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried |
Show registry wordingEligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses. | ||
| Zagreb regimen (CD4+ T cell count <350 cells/mm³) | Experimental | Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried |
Show registry wordingEligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count \<350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7 and 1 dose on day 21, for a total of 4 doses. | ||
| Essen regimen (CD4+ T cell count <350 cells/mm³) | Experimental | Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried |
Show registry wordingEligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count \<350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses. | ||
Primary endpoints
Registered primary outcome measures; 2 primary.
| Measure | Time frame |
|---|---|
| Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination course | 14 days after completion of the full vaccination course |
Show registry wordingSeroconversion rate and GMC of rabies virus neutralizing antibodies among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by the rapid fluorescent focus inhibition test (RFFIT). | |
| Incidence of adverse events after vaccination | 30 minutes, 0-7 days, and 8-14 days after each vaccine dose |
Show registry wordingIncidence of immediate local and systemic adverse events recorded within 30 minutes after each vaccination; incidence of solicited local and systemic adverse events collected 0-7 days after each dose; incidence of unsolicited adverse events collected 8-14 days after each dose. Adverse events are defined as any untoward medical occurrence in a participant administered vaccine, not necessarily having a causal relationship with vaccination. | |
Lead sponsor's other trials
Liaoning Chengda Biotechnology CO., LTD, most recent start first.
Similar trials
Same condition (Rabies) and phase, most recent start first.
+7 more trials See the condition page